SCHEMBL1892299

SCHEMBL1892299

CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC37A4 O43826 2/20 0.43
MCL1 Q07820 3/20 0.41
BCL2 P10415 2/20 0.41
NQO1 P15559 1/20 0.40
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 2/20 0.40
GAA P10253 2/20 0.40
MAPK1 P28482 2/20 0.40
JAK2 O60674 1/20 0.40
PKM P14618 1/20 0.40
MPI P34949 1/20 0.40
HTT P42858 1/20 0.40
BLM P54132 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BCL2L1 Q07817 1/20 0.39
BCL2A1 Q16548 1/20 0.39
ELANE P08246 2/20 0.39
CTSG P08311 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1885850 0.92 ESR1 (0.40) SLC37A4MCL1BCL2NQO1KDM4E
SCHEMBL24089057 0.88 SLC37A4 (0.38) SLC37A4MCL1BCL2NQO1KDM4E
SCHEMBL1893025 0.88 BCL2 (0.50) SLC37A4MCL1BCL2KDM4EALDH1A1
SCHEMBL1887255 0.87 LMNA (0.36) SLC37A4MCL1BCL2KDM4EALDH1A1
SCHEMBL1889138 0.87 PGAM1 (0.45) SLC37A4MCL1BCL2BCL2L1BCL2A1
SCHEMBL24089139 0.80 SLC37A4 (0.32) SLC37A4KDM4EALDH1A1
SCHEMBL19424216 0.80 BCL2 (0.40) SLC37A4MCL1BCL2KDM4EALDH1A1
SCHEMBL29583580 0.79 SLC37A4 (0.37) SLC37A4MCL1BCL2NQO1KDM4E
SCHEMBL1891842 0.79 BCL2 (0.37) SLC37A4MCL1BCL2KDM4EALDH1A1
SCHEMBL1893084 0.78 BCL2L1 (0.54) SLC37A4MCL1BCL2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210379078-A1 Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor UNITY BIOTECHNOLOGY, INC. 2021-12-09 US disclosed
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-8937193-B2 Apogossypolone derivatives as anticancer agents SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2015-01-20 US disclosed
US-20110112112-A1 APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 SLC37A4 3610/4885MCL1 137/4885BCL2 520/4885
US-20110112112-A1 APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS CYP17A1, HSD17B7, CYP27A1 SLC37A4 1590/4885MCL1 34/4885BCL2 142/4885
US-20210379078-A1 Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor MCL1, BCL2, BCL2L1 SLC37A4 4603/4885MCL1 1/4885BCL2 2/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA SLC37A4 3920/4885MCL1 8/4885BCL2 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.